Amedeo Smart

Free Medical Literature Service


 

Amedeo

Bladder Cancer

  Free Subscription

Articles published in
J Urol
    July 2021
  1. SCHOENBERG M, Steinberg G
    Rethinking the Treatment of Recurrent Nonmuscle-Invasive Bladder Cancer.
    J Urol. 2021;206:7-9.
    >> Share

  2. PIERETTI A, Krasnow R, Drumm M, Gusev A, et al
    Complications and Outcomes of Salvage Cystectomy after Trimodality Therapy.
    J Urol. 2021;206:29-36.
    >> Share

    June 2021
  3. ZHANG R, Zang J, Xie F, Zhang Y, et al
    Urinary Molecular Pathology for Patients with Newly Diagnosed Urothelial Bladder Cancer.
    J Urol. 2021 Jun 1:101097JU0000000000001878. doi: 10.1097/JU.0000000000001878.
    >> Share

    May 2021
  4. CHAKIRYAN NH, Jiang DD, Gillis KA, Green E, et al
    Pathologic Downstaging and Survival Outcomes Associated with Neoadjuvant Chemotherapy for Variant Histology Muscle Invasive Bladder Cancer.
    J Urol. 2021 May 25:101097JU0000000000001855. doi: 10.1097/JU.0000000000001855.
    >> Share

  5. MARTINI A, Afferi L, Zamboni S, Schultz JG, et al
    Oncologic Surveillance for Variant Histology Bladder Cancer after Radical Cystectomy.
    J Urol. 2021 May 25:101097JU0000000000001886. doi: 10.1097/JU.0000000000001886.
    >> Share

  6. WOLDU SL, Ng CK, Loo RK, Slezak JM, et al
    Evaluation of the New American Urological Association Guidelines Risk Classification for Hematuria.
    J Urol. 2021;205:1387-1393.
    >> Share

  7. HASHEM A, Abol-Enein H, Laymon M, Abdellutif MM, et al
    A Randomized Trial to Examine the Utility of Mebeverine on the Early Return of Continence Following Orthotopic Bladder Substitution.
    J Urol. 2021;205:1400-1406.
    >> Share

  8. MATULEWICZ RS, Basak R, Zambrano I, Dearing BA, et al
    Patterns of Current Cigarette Smoking, Quit Attempts and Cessation Counseling among Survivors of Smoking-Related and Nonsmoking-Related Urological Malignancies: A Nationally Representative Cross-Sectional Analysis.
    J Urol. 2021;205:1444-1451.
    >> Share

  9. WYMER KM, Sharma V, Saigal CS, Chamie K, et al
    Cost-Effectiveness Analysis of Pembrolizumab for Bacillus Calmette-Guerin-Unresponsive Carcinoma In Situ of the Bladder.
    J Urol. 2021;205:1326-1335.
    >> Share

    April 2021
  10. BREE KK, Hensley PJ, Westerman MB, Kokorovic A, et al
    Contemporary Rates of Gynecologic Organ Involvement in Females With Muscle Invasive Bladder Cancer: A Retrospective Review of Women Undergoing Radical Cystectomy Following Neoadjuvant Chemotherapy.
    J Urol. 2021 Apr 19:101097JU0000000000001784. doi: 10.1097/JU.0000000000001784.
    >> Share

  11. BAUSCH K, Halbeisen FS, Aghlmandi S, Sutter SU, et al
    Reply by Authors.
    J Urol. 2021;205:998.
    >> Share

  12. SOUNTOULIDES P, Pyrgidis N, Brookman-May S, Mykoniatis I, et al
    Does Ureteral Stenting Increase the Risk of Metachronous Upper Tract Urothelial Carcinoma in Patients with Bladder Tumors? A Systematic Review and Meta-analysis.
    J Urol. 2021;205:956-966.
    >> Share

  13. SHVERO A, Abu-Ghanem Y, Laufer M, Dotan ZA, et al
    Endoscopic Treatment for Large Multifocal Upper Tract Urothelial Carcinoma.
    J Urol. 2021;205:1039-1046.
    >> Share

    March 2021
  14. LUSTY A, Doiron RC, Booth CM, Whitehead M, et al
    No Outcome Differences after Cystectomy Between Patients with de Novo Muscle-Invasive Bladder Cancer Compared to Progressors: A Retrospective Population-Based Study.
    J Urol. 2021 Mar 30:101097JU0000000000001715. doi: 10.1097/JU.0000000000001715.
    >> Share

  15. YANAGISAWA T, Miki J, Sakanaka K, Fukuokaya W, et al
    Clinical Significance of Horizontal and Vertical Margin of En Bloc Resection for Non-Muscle Invasive Bladder Cancer.
    J Urol. 2021 Mar 29:101097JU0000000000001735. doi: 10.1097/JU.0000000000001735.
    >> Share


  16. Erratum: Perceptions of Link between Smoking and Bladder Cancer among United States Adults.
    J Urol. 2021;205:942.
    >> Share


  17. Erratum: Microbiome of Catheter Collected Urine in Males with Bladder Cancer According to Disease Stage.
    J Urol. 2021;205:942.
    >> Share

  18. DAS A, Cohen JE, Ko OS, Jordan BJ, et al
    Surgeon Scorecards Improve Muscle Sampling on Transurethral Resection of Bladder Tumor and Recurrence Outcomes in Patients with Nonmuscle Invasive Bladder Cancer.
    J Urol. 2021;205:693-700.
    >> Share

  19. TAGUCHI S, Tambo M, Watanabe M, Machida H, et al
    Prospective Validation of Vesical Imaging-Reporting and Data System Using a Next-Generation Magnetic Resonance Imaging Scanner-Is Denoising Deep Learning Reconstruction Useful?
    J Urol. 2021;205:686-692.
    >> Share

  20. SWAMI U, Haaland B, Kessel A, Nussenzveig R, et al
    Comparative Effectiveness of Immune Checkpoint Inhibitors in Patients with Platinum Refractory Advanced Urothelial Carcinoma.
    J Urol. 2021;205:709-717.
    >> Share

    February 2021
  21. BHAT A, Kwon D, Soodana-Prakash N, Mouzannar A, et al
    Surveillance Intensity in Intermediate Risk Nonmuscle Invasive Bladder Cancer: Revisiting the Optimal Timing and Frequency of Cystoscopy.
    J Urol. 2021 Feb 22:101097JU0000000000001689. doi: 10.1097/JU.0000000000001689.
    >> Share

  22. ZHU D, Srivastava A, Agalliu I, Fram E, et al
    Finasteride Use and Risk of Bladder Cancer in a Multiethnic Population.
    J Urol. 2021 Feb 22:101097JU0000000000001694. doi: 10.1097/JU.0000000000001694.
    >> Share

  23. MICHELLE R, Liguori G, Trombetta C
    Antimicrobial Prophylaxis for Postoperative Urinary Tract Infections in Transurethral Resection of Bladder Tumors: A Systematic Review and Meta-analysis. Letter.
    J Urol. 2021 Feb 12:101097JU0000000000001649. doi: 10.1097/JU.0000000000001649.
    >> Share

  24. ZIBELMAN M, Asghar AM, Parker DC, O'Neill J, et al
    Cystoscopy and Systematic Bladder Tissue Sampling in Predicting pT0 Bladder Cancer: A Prospective Trial.
    J Urol. 2021 Feb 4:101097JU0000000000001602. doi: 10.1097/JU.0000000000001602.
    >> Share

  25. FURRER MA, Kiss B, Studer UE, Wuethrich PY, et al
    Seminal Vesical Sparing Cystectomy in Bladder Cancer Patients is Feasible with Good Functional Results without Impairing Oncological Outcomes: A Longitudinal Long-Term Propensity-Matched Single Center Study.
    J Urol. 2021 Feb 3:101097JU0000000000001635. doi: 10.1097/JU.0000000000001635.
    >> Share

  26. GHOREIFI A, Djaladat H
    Re: Intra-Operative Ureteral Stent Use at Radical Cystectomy is Associated with Higher 30-Day Complication RatesDonat SM, Tan KS, Jibara G, Dalbagni G, Arslan Carlon V, Sandhu J J Urol 2020; doi:10.1097/JU.0000000000001329.
    J Urol. 2021;205:335-336.
    >> Share

  27. DONAT SM, Tan KS, Jibara G, Dalbagni G, et al
    Intraoperative Ureteral Stent Use at Radical Cystectomy is Associated with Higher 30-Day Complication Rates.
    J Urol. 2021;205:483-490.
    >> Share

  28. CACCIAMANI GE, Medina L, Lin-Brande M, Tafuri A, et al
    Timing, Patterns and Predictors of 90-Day Readmission Rate after Robotic Radical Cystectomy.
    J Urol. 2021;205:491-499.
    >> Share

  29. ELSAYED AS, Gibson S, Jing Z, Wijburg C, et al
    Rates and Patterns of Recurrences and Survival Outcomes after Robot-Assisted Radical Cystectomy: Results from the International Robotic Cystectomy Consortium.
    J Urol. 2021;205:407-413.
    >> Share

  30. GALLIOLI A, Territo A, Mercade A, Fontana M, et al
    The Impact of Ureteroscopy following Computerized Tomography Urography in the Management of Upper Tract Urothelial Carcinoma.
    J Urol. 2021;205:392-399.
    >> Share

  31. WEI XX, Werner L, Teo MY, Rosenberg JE, et al
    Sequencing of PD-1/L1 Inhibitors and Carboplatin Based Chemotherapy for Cisplatin Ineligible Metastatic Urothelial Carcinoma.
    J Urol. 2021;205:414-419.
    >> Share

  32. CHESNUT GT, Tin AL, Sjoberg DD, Jang B, et al
    Electronic Rapid Fitness Assessment Identifies Factors Associated with Adverse Early Postoperative Outcomes following Radical Cystectomy.
    J Urol. 2021;205:400-406.
    >> Share

    January 2021
  33. MATULAY JT, Li R, Hensley PJ, Brooks NA, et al
    Contemporary Outcomes of Patients with Non-Muscle Invasive Bladder Cancer Treated with BCG Therapy: Implications for Clinical Trial Design.
    J Urol. 2021 Jan 27:101097JU0000000000001633. doi: 10.1097/JU.0000000000001633.
    >> Share

  34. YANAGISAWA T, Miki J, Yorozu T, Iwatani K, et al
    Vertical Lamina Propria Invasion Diagnosed by En Bloc Transurethral Resection is a Significant Predictor of Progression for pT1 Bladder Cancer.
    J Urol. 2021 Jan 27:101097JU0000000000001630. doi: 10.1097/JU.0000000000001630.
    >> Share

  35. WEIN AJ
    Voiding Function and Dysfunction, Bladder Physiology and Pharmacology, and Female Urology.
    J Urol. 2021;205:309-312.
    >> Share

  36. MEEKS JJ
    Editorial Comment.
    J Urol. 2021;205:107.
    >> Share

  37. HATAKEYAMA S, Hamano I, Ohyama C
    Editorial Comment.
    J Urol. 2021;205:107.
    >> Share

  38. HAUTMANN RE, Volkmer B, Egghart G, Frohneberg D, et al
    Functional Outcome and Complications following Ileal Neobladder Reconstruction in Male Patients without Tumor Recurrence. More than 35 Years of Experience from a Single Center.
    J Urol. 2021;205:174-182.
    >> Share

    December 2020
  39. PETRUZELLA S, Bochner BH, Kenney J, Whiting K, et al
    Examining the Accuracy of Self-Reported Smoking-Related Exposure Among Recently Diagnosed Non-muscle Invasive Bladder Cancer Patients.
    J Urol. 2020 Dec 24:101097JU0000000000001571. doi: 10.1097/JU.0000000000001571.
    >> Share

  40. KIRSCHNER AN, Wang J, Rajkumar-Calkins A, Neuzil KE, et al
    Intravesical Anti-PD-1 Immune Checkpoint Inhibition Treats Urothelial Bladder Cancer in a Mouse Model.
    J Urol. 2020 Dec 24:101097JU0000000000001576. doi: 10.1097/JU.0000000000001576.
    >> Share

  41. BAUSCH K, Halbeisen FS, Aghlmandi S, Sutter SU, et al
    Antimicrobial Prophylaxis for Postoperative Urinary Tract Infections in Transurethral Resection of Bladder Tumors: A Systematic Review and Meta-analysis.
    J Urol. 2020 Dec 7:101097JU0000000000001513. doi: 10.1097/JU.0000000000001513.
    >> Share

  42. CHANG SS
    Re: Impact of Adjuvant Chemotherapy in Patients with Adverse Features and Variant Histology at Radical Cystectomy for Muscle-Invasive Carcinoma of the Bladder: Does Histologic Subtype Matter?
    J Urol. 2020;204:1378.
    >> Share

  43. MORI K, Abufaraj M, Mostafaei H, Quhal F, et al
    A Systematic Review and Meta-Analysis of Variant Histology in Urothelial Carcinoma of the Bladder Treated with Radical Cystectomy.
    J Urol. 2020;204:1129-1140.
    >> Share

    November 2020
  44. DE JONG FC, Hoedemaeker RF, Kvikstad V, Mensink JTM, et al
    T1-Substaging of Non-muscle Invasive Bladder Cancer is Associated with BCG-Failure and Improves Patient Stratification at Diagnosis.
    J Urol. 2020 Nov 16:101097JU0000000000001422. doi: 10.1097/JU.0000000000001422.
    >> Share

  45. YIN G, Tang J, Wang L
    Re: A Urine Based Genomic Assay to Triage Patients with Hematuria for CystoscopyK. E. M. van Kessel, J. J. de Jong, A. C. J. Ziel-van der Made, H. Roshani, S. M. Haensel, J. H. Wolterbeek, E. R. Boeve, E. H. G. M. Oomens, N. J. van Casteren, M. Krispi
    J Urol. 2020;204:1062.
    >> Share

  46. HANNA PT, Peterson M, Albersheim J, Drawz P, et al
    Acute Kidney Injury following Enhanced Recovery after Surgery in Patients Undergoing Radical Cystectomy.
    J Urol. 2020;204:982-988.
    >> Share

  47. WANG DS
    Re: Epidural Anesthesia is Associated with Increased Complications in Cystectomy Patients: A NSQIP Analysis.
    J Urol. 2020;204:1072-1073.
    >> Share

    October 2020
  48. MYRIE AK, Matulewicz RS
    Perceptions of the Link Between Smoking and Bladder Cancer Among United States Adults.
    J Urol. 2020 Oct 14:101097JU0000000000001415. doi: 10.1097/JU.0000000000001415.
    >> Share

  49. SCHMIDT A, Warmann SW, Eckert F, Ellerkamp V, et al
    The Role of Reconstructive Surgery and Brachytherapy in Pediatric Bladder/Prostate Rhabdomyosarcoma.
    J Urol. 2020;204:825-834.
    >> Share

  50. ALMASSI N, Cha EK, Vertosick EA, Huang C, et al
    Trends in Management and Outcomes among Patients with Urothelial Carcinoma Undergoing Radical Cystectomy from 1995 to 2015: The Memorial Sloan Kettering Experience.
    J Urol. 2020;204:677-684.
    >> Share

  51. CACCIAMANI GE, Ghodoussipour S, Mari A, Gill KS, et al
    Association between Smoking Exposure, Neoadjuvant Chemotherapy Response and Survival Outcomes following Radical Cystectomy: Systematic Review and Meta-Analysis.
    J Urol. 2020;204:649-660.
    >> Share

    September 2020
  52. CHANG SS
    Re: Bacillus Calmette-Guerin (BCG) Therapy Lowers the Incidence of Alzheimer's Disease in Bladder Cancer Patients.
    J Urol. 2020 Sep 21:101097JU000000000000128202.
    >> Share

  53. CHANG SS
    Re: Care Quality and Variability in the Use of Intravesical Therapy for Initial Treatment of Nonmuscle Invasive Bladder Cancer within a Large, Diverse Integrated Delivery System.
    J Urol. 2020 Sep 21:101097JU000000000000128201.
    >> Share

  54. ATALA A
    Re: A Genetically Defined Disease Model Reveals That Urothelial Cells Can Initiate Divergent Bladder Cancer Phenotypes.
    J Urol. 2020 Sep 21:101097JU000000000000128501.
    >> Share

  55. REGMI SK, Kalapara A, Konety BR
    The Need for Interim Assessment of Neoadjuvant Chemotherapy Response for Muscle Invasive Bladder Cancer: Can We Help Prevent Definitive Treatment Delay in Non-responders?
    J Urol. 2020 Sep 18:101097JU0000000000001381. doi: 10.1097/JU.0000000000001381.
    >> Share

  56. LAVIANA AA, Stone BV, Avulova S
    Editorial Comment.
    J Urol. 2020;204:458-459.
    >> Share

  57. KRETSCHMER A
    Editorial Comment.
    J Urol. 2020;204:458.
    >> Share

  58. CHANG SS
    Editorial Comment.
    J Urol. 2020;204:449.
    >> Share

  59. CADEDDU JA
    Re: Long-Term Oncological Outcomes from an Early Phase Randomised Controlled Three-Arm Trial of Open, Robotic, and Laparoscopic Radical Cystectomy (CORAL).
    J Urol. 2020;204:598.
    >> Share

  60. DASON S, Cha EK, Falavolti C, Vertosick EA, et al
    Late Recurrences Following Radical Cystectomy Have Distinct Prognostic and Management Considerations.
    J Urol. 2020;204:460-465.
    >> Share

    August 2020
  61. ORESTA B, Braga D, Lazzeri M, Frego N, et al
    The Microbiome of Catheter-Collected Urine in Males with Bladder Cancer according to Disease Stage.
    J Urol. 2020 Aug 28:101097JU0000000000001336. doi: 10.1097/JU.0000000000001336.
    >> Share

  62. CHANG SS
    Re: Surgical Safety of Radical Cystectomy and Pelvic Lymph Node Dissection following Neoadjuvant Pembrolizumab in Patients with Bladder Cancer: Prospective Assessment of Perioperative Outcomes from the PURE-01 Trial.
    J Urol. 2020 Aug 21:101097JU0000000000001260. doi: 10.1097/JU.0000000000001260.
    >> Share

  63. CHANG SS
    Re: Chemoablation with Intensive Intravesical Mitomycin C Treatment: A New Approach for Non-Muscle-Invasive Bladder Cancer.
    J Urol. 2020 Aug 21:101097JU000000000000126001.
    >> Share

  64. CHANG SS
    Re: Cigarette Smoking is Associated with Adverse Pathological Response and Increased Disease Recurrence amongst Patients with Muscle-Invasive Bladder Cancer Treated with Cisplatin-Based Neoadjuvant Chemotherapy and Radical Cystectomy: A Single-Centre
    J Urol. 2020 Aug 21:101097JU000000000000126002.
    >> Share

  65. HAJIRAN A, Azizi M, Aydin AM, Zemp L, et al
    Pathologic and Survival Outcomes Associated with Variant Histology Bladder Cancers Managed with Cystectomy with or Without Neoadjuvant Chemotherapy.
    J Urol. 2020 Aug 12:101097JU0000000000001325. doi: 10.1097/JU.0000000000001325.
    >> Share

  66. LIM A, Gregg JR
    Editorial Comment.
    J Urol. 2020;204:245-246.
    >> Share

  67. CHENG L
    Editorial Comment.
    J Urol. 2020;204:246.
    >> Share

  68. DE JONG JJ, Liu Y, Boorjian SA, Bivalacqua TJ, et al
    A Genomic Classifier for Predicting Clinically Aggressive Luminal Bladder Tumors with Higher Rates of Pathological Up Staging.
    J Urol. 2020;204:239-246.
    >> Share

  69. KIM DK, Kim JW, Ro JY, Lee HS, et al
    Plasmacytoid Variant Urothelial Carcinoma of the Bladder: A Systematic Review and Meta-Analysis of Clinicopathological Features and Survival Outcomes.
    J Urol. 2020;204:215-223.
    >> Share

  70. CHANG SS
    Re: Smoking Cessation: A Report of the Surgeon General.
    J Urol. 2020;204:384.
    >> Share

  71. DASON S, Wong NC, Donahue TF, Meier A, et al
    Utility of Routine Preoperative (18)F-Fluorodeoxyglucose Positron Emission Tomography/Computerized Tomography in Identifying Pathological Lymph Node Metastases at Radical Cystectomy.
    J Urol. 2020;204:254-259.
    >> Share

  72. DECASTRO GJ, Sui W, Pak JS, Lee SM, et al
    A Phase I Trial of Intravesical Cabazitaxel, Gemcitabine and Cisplatin for the Treatment of Nonmuscle Invasive bacillus Calmette-Guerin Unresponsive or Recurrent/Relapsing Urothelial Carcinoma of the Bladder.
    J Urol. 2020;204:247-253.
    >> Share

    July 2020
  73. OSTERMAN CK, Deal AM, McCloskey H, Nyrop KA, et al
    Impairment and Longitudinal Recovery of Older Adults Treated with Radical Cystectomy for Muscle-Invasive Bladder Cancer.
    J Urol. 2020 Jul 27:101097JU0000000000001323. doi: 10.1097/JU.0000000000001323.
    >> Share

  74. CHANG SS
    Re: STAG2 is a Biomarker for Prediction of Recurrence and Progression in Papillary Non-Muscle-Invasive Bladder Cancer.
    J Urol. 2020 Jul 27:101097JU000000000000121902.
    >> Share

  75. ATALA A
    Re: The CUL4B-miR-372/373-PIK3CA-AKT Axis Regulates Metastasis in Bladder Cancer.
    J Urol. 2020 Jul 27:101097JU000000000000122201.
    >> Share

  76. TAN WS, Kelly JD
    Editorial Comment.
    J Urol. 2020;204:56-57.
    >> Share

  77. SHKOLYAR E, Mach KE, Liao JC
    Editorial Comment.
    J Urol. 2020;204:56.
    >> Share

  78. MORI K, Mostafaei H, Enikeev DV, Lysenko I, et al
    Differential Effect of Sex on Outcomes after Radical Surgery for Upper Tract and Bladder Urothelial Carcinoma: A Systematic Review and Meta-Analysis.
    J Urol. 2020;204:58-62.
    >> Share

  79. VAN KESSEL KEM, de Jong JJ, Ziel-van der Made ACJ, Roshani H, et al
    A Urine Based Genomic Assay to Triage Patients with Hematuria for Cystoscopy.
    J Urol. 2020;204:50-57.
    >> Share

  80. CHANG SS
    Re: Adjuvant Chemotherapy vs Observation for Patients with Adverse Pathologic Features at Radical Cystectomy Previously Treated with Neoadjuvant Chemotherapy.
    J Urol. 2020;204:184.
    >> Share

    June 2020
  81. CHANG SS
    Re: National Cancer Database Comparison of Radical Cystectomy vs Chemoradiotherapy for Muscle-Invasive Bladder Cancer: Implications of Using Clinical vs Pathologic Staging.
    J Urol. 2020 Jun 30:101097JU0000000000001175. doi: 10.1097/JU.0000000000001175.
    >> Share

  82. CHANG SS
    Re: Identification and Validation of Stromal Immunotype Predict Survival and Benefit from Adjuvant Chemotherapy in Patients with Muscle-Invasive Bladder Cancer.
    J Urol. 2020 Jun 30:101097JU000000000000117501.
    >> Share

  83. ATALA A
    Re: Therapeutically Actionable PAK4 is Amplified, Overexpressed, and Involved in Bladder Cancer Progression.
    J Urol. 2020 Jun 18:101097JU000000000000117901.
    >> Share

  84. CHANG SS
    Re: The Impact of Non-Urothelial Variant Histology on Oncological Outcomes following Radical Cystectomy.
    J Urol. 2020;203:1060.
    >> Share

  85. SZYMANSKI KM, Misseri R, Whittam B, Hollowell N, et al
    Additional Surgeries after Bladder Augmentation in Patients with Spina Bifida in the 21st Century.
    J Urol. 2020;203:1207-1213.
    >> Share

  86. FOERSTER B, Abufaraj M, Petros F, Azizi M, et al
    Efficacy of Preoperative Chemotherapy for High Risk Upper Tract Urothelial Carcinoma.
    J Urol. 2020;203:1101-1108.
    >> Share

    May 2020
  87. GRIEBLING TL
    Re: Rate and Determinants of Completing Neoadjuvant Chemotherapy in Medicare Beneficiaries with Bladder Cancer: A SEER-Medicare Analysis.
    J Urol. 2020 May 13:101097JU000000000000110204.
    >> Share

  88. CHANG SS
    Re: Assessment of Quality of Life, Information, and Supportive Care Needs in Patients with Muscle and Non-Muscle Invasive Bladder Cancer across the Illness Trajectory.
    J Urol. 2020 May 12:101097JU000000000000111402.
    >> Share

  89. ATALA A
    Re: A Genetically Defined Disease Model Reveals that Urothelial Cells Can Initiate Divergent Bladder Cancer Phenotypes.
    J Urol. 2020 May 12:101097JU0000000000001117. doi: 10.1097/JU.0000000000001117.
    >> Share

  90. CHANG SS
    Re: Association between Treatment of Superficial Bladder Cancer and 10-Year Mortality in Older Adults with Multiple Chronic Conditions.
    J Urol. 2020 May 12:101097JU000000000000111401.
    >> Share

  91. CHANG SS
    Re: PD-L1 Expression in Tumor Cells and the Immunologic Milieu of Bladder Carcinomas: A Pathologic Review of 165 Cases.
    J Urol. 2020;203:880.
    >> Share

  92. WITJES JA
    Editorial Comment.
    J Urol. 2020;203:908-909.
    >> Share

    April 2020
  93. ROUPRET M, Gontero P, McCracken SRC, Dudderidge T, et al
    Diagnostic Accuracy of MCM5 for the Detection of Recurrence in Non Muscle Invasive Bladder Cancer Follow up: A Blinded, Prospective Cohort, Multicentric European Study.
    J Urol. 2020 Apr 21:101097JU0000000000001084. doi: 10.1097/JU.0000000000001084.
    >> Share

  94. ATALA A
    Re: Hypermethylation of FOXA1 and Allelic Loss of PTEN Drive Squamous Differentiation and Promote Heterogeneity in Bladder Cancer.
    J Urol. 2020 Apr 9:101097JU0000000000001058. doi: 10.1097/JU.0000000000001058.
    >> Share

  95. CHANG SS
    Re: Bladder Preservation with Twice-a-Day Radiation plus Fluorouracil/Cisplatin or Once Daily Radiation plus Gemcitabine for Muscle-Invasive Bladder Cancer: NRG/RTOG 0712-A Randomized Phase II Trial.
    J Urol. 2020 Apr 9:101097JU0000000000001055. doi: 10.1097/JU.0000000000001055.
    >> Share

  96. BECERRA MF, Venkatramani V, Reis IM, Soodana-Prakash N, et al
    Health-Related Quality of Life of Patients with Bladder Cancer in the RAZOR Trial - A Multi-Institutional Randomized Trial Comparing Robot versus Open Radical Cystectomy.
    J Urol. 2020 Apr 9:101097JU0000000000001029. doi: 10.1097/JU.0000000000001029.
    >> Share

  97. CHANG SS
    Re: Implementation of a Perioperative Venous Thromboembolism Prophylaxis Program for Patients Undergoing Radical Cystectomy on an Enhanced Recovery after Surgery Protocol.
    J Urol. 2020;203:660.
    >> Share

    March 2020
  98. SHARMA V, Wymer KM, Borah BJ, Saigal CS, et al
    Cost-Effectiveness of Maintenance BCG for Intermediate and High Risk Non-Muscle Invasive Bladder Cancer.
    J Urol. 2020 Mar 19:101097JU0000000000001023. doi: 10.1097/JU.0000000000001023.
    >> Share

  99. CHANG SS
    Re: The Challenges of Bacillus of Calmette-Guerin (BCG) Therapy for High Risk Non Muscle Invasive Bladder Cancer Treatment in Older Patients.
    J Urol. 2020 Mar 17:101097JU000000000000099902.
    >> Share

  100. NABAVIZADEH R, Joshi SS
    Editorial Comment.
    J Urol. 2020;203:511.
    >> Share

  101. MONTORSI F, Moschini M, Gallina A, Briganti A, et al
    Re: Ten-Year Oncologic Outcomes following Robot-Assisted Radical Cystectomy: Results from the International Robotic Cystectomy Consortium.
    J Urol. 2020;203:624.
    >> Share

  102. MULLER G, Butea-Bocu M, Brock O, Hanske J, et al
    Association between Development of Metabolic Acidosis and Improvement of Urinary Continence after Ileal Neobladder Creation.
    J Urol. 2020;203:585-590.
    >> Share

  103. ZHANG JH, Ericson KJ, Thomas LJ, Knorr J, et al
    Large Single Institution Comparison of Perioperative Outcomes and Complications of Open Radical Cystectomy, Intracorporeal Robot-Assisted Radical Cystectomy and Robotic Extracorporeal Approach.
    J Urol. 2020;203:512-521.
    >> Share

  104. VENKATRAMANI V, Reis IM, Castle EP, Gonzalgo ML, et al
    Predictors of Recurrence, and Progression-Free and Overall Survival following Open versus Robotic Radical Cystectomy: Analysis from the RAZOR Trial with a 3-Year Followup.
    J Urol. 2020;203:522-529.
    >> Share

    February 2020
  105. INABA H, Kimura T, Onuma H, Sato S, et al
    Tumor Location and Pathological Features of Latent and Incidental Prostate Cancer in Contemporary Japanese Men.
    J Urol. 2020 Feb 18:101097JU0000000000000804. doi: 10.1097/JU.0000000000000804.
    >> Share

  106. ATALA A
    Re: 5-Methylcytosine Promotes Pathogenesis of Bladder Cancer through Stabilizing mRNAs.
    J Urol. 2020 Feb 12:101097JU0000000000000781. doi: 10.1097/JU.0000000000000781.
    >> Share

  107. ATALA A
    Re: Inhibition of a G9a/DNMT Network Triggers Immune-Mediated Bladder Cancer Regression.
    J Urol. 2020 Feb 12:101097JU000000000000078101.
    >> Share

  108. WEINER AB, Kundu SD
    Editorial Comment.
    J Urol. 2020;203:290-291.
    >> Share

  109. CHANG SS
    Re: Effectiveness of Adjuvant Chemotherapy after Radical Cystectomy for Locally Advanced and/or Pelvic Lymph Node-Positive Muscle-Invasive Urothelial Carcinoma of the Bladder: A Propensity Score-Weighted Competing Risks Analysis.
    J Urol. 2020;203:250.
    >> Share

    January 2020
  110. GARNIER S, Vendrell J, Boillot B, Karsenty G, et al
    Malignancy after Augmentation Enterocystoplasty: A Nationwide Study of Natural History, Prognosis and Oncogene Panel Analysis.
    J Urol. 2020 Jan 20:101097JU0000000000000752. doi: 10.1097/JU.0000000000000752.
    >> Share

  111. ATALA A
    Re: Epigenetic Loss of AOX1 Expression via EZH2 Leads to Metabolic Deregulations and Promotes Bladder Cancer Progression.
    J Urol. 2020 Jan 13:101097JU000000000000073202.
    >> Share

  112. CHANG SS
    Re: Multicenter Prospective Phase II Trial of Neoadjuvant Dose-Dense Gemcitabine plus Cisplatin in Patients with Muscle-Invasive Bladder Cancer.
    J Urol. 2020 Jan 13:101097JU0000000000000729. doi: 10.1097/JU.0000000000000729.
    >> Share

  113. CHANG SS
    Re: Predictive Factors for Residual Cancer in Second Transurethral Resection for Non-Muscle-Invasive Bladder Cancer.
    J Urol. 2020 Jan 13:101097JU000000000000072902.
    >> Share

  114. SIEGEL C
    Re: Delayed (18)F FDG PET/CT Imaging in the Assessment of Residual Tumors after Transurethral Resection of Bladder Cancer.
    J Urol. 2020 Jan 7:101097JU0000000000000718. doi: 10.1097/JU.0000000000000718.
    >> Share

  115. GRIEBLING TL
    Re: Frailty as a Predictor of Complications after Radical Cystectomy: A Prospective Study of Various Preoperative Assessments.
    J Urol. 2020;203:9.
    >> Share

  116. ALDHAAM NA, Elsayed AS, Jing Z, Richstone L, et al
    Neoadjuvant Chemotherapy is Not Associated with Adverse Perioperative Outcomes after Robot-Assisted Radical Cystectomy: A Case for Increased Use from the IRCC.
    J Urol. 2020;203:57-61.
    >> Share

  117. CHECK DK, Leo MC, Banegas MP, Bulkley JE, et al
    Decision Regret Related to Urinary Diversion Choice among Patients Treated with Cystectomy.
    J Urol. 2020;203:159-163.
    >> Share

    December 2019
  118. STEINBERG RL, Thomas LJ, Brooks N, Mott SL, et al
    Multi-Institution Evaluation of Sequential Gemcitabine and Docetaxel as Rescue Therapy of Non-muscle Invasive Bladder Cancer.
    J Urol. 2019 Dec 10:101097JU0000000000000688. doi: 10.1097/JU.0000000000000688.
    >> Share

  119. CHANG SS
    Re: Radiofrequency-Induced Thermo-Chemotherapy Effect versus a Second Course of Bacillus Calmette-Guerin or Institutional Standard in Patients with Recurrence of Non-Muscle-Invasive Bladder Cancer following Induction or Maintenance Bacillus Calmette-G
    J Urol. 2019 Dec 3:101097JU0000000000000676. doi: 10.1097/JU.0000000000000676.
    >> Share

  120. WEIN AJ
    Re: Long-Term Follow-Up after Cystectomy for Bladder Pain Syndrome: Pain Status, Sexual Function and Quality of Life.
    J Urol. 2019;202:1101-1102.
    >> Share

  121. LENIS AT
    Editorial Comment.
    J Urol. 2019;202:1134-1135.
    >> Share

  122. ALBERSHEIM J, Sathianathen NJ, Zabell J, Renier J, et al
    Skeletal Muscle and Fat Mass Indexes Predict Discharge Disposition after Radical Cystectomy.
    J Urol. 2019;202:1143-1149.
    >> Share

  123. SIGHINOLFI MC, Rocco B, Micali S, Bianchi G, et al
    Re: Accurate Quantification of Residual Cancer Cells in Pelvic Washing Reveals Association with Cancer Recurrence following Robot-Assisted Radical Cystectomy.
    J Urol. 2019;202:1271-1272.
    >> Share

  124. RASKOLNIKOV D, Brown B, Holt SK, Ball AL, et al
    Reduction of Pain during Flexible Cystoscopy: A Systematic Review and Meta-Analysis.
    J Urol. 2019;202:1136-1142.
    >> Share

  125. AL HUSSEIN AL AWAMLH B, Shoag JE, Ravikumar V, Posada L, et al
    Association of Smoking and Death from Genitourinary Malignancies: Analysis of the National Longitudinal Mortality Study.
    J Urol. 2019;202:1248-1254.
    >> Share

    November 2019
  126. SCHAEFFER EM
    Re: Reduced Recurrence of Low-Grade Papillary Bladder Tumors Associated with Asymptomatic Bacteriuria.
    J Urol. 2019;202:849.
    >> Share

  127. ATALA A
    Re: Recurrent Activating Mutations of PPARgamma Associated with Luminal Bladder Tumors.
    J Urol. 2019;202:869.
    >> Share

  128. PEYTON CC, Reich RR, Tang D, Alford B, et al
    Identifying and Codifying Complications after Radical Cystectomy: Comparison of Administrative Diagnostic and Procedure Codes, and Clinical Chart Review.
    J Urol. 2019;202:913-919.
    >> Share

  129. HUSSEIN AA, Elsayed AS, Aldhaam NA, Jing Z, et al
    Ten-Year Oncologic Outcomes Following Robot-Assisted Radical Cystectomy: Results from the International Robotic Cystectomy Consortium.
    J Urol. 2019;202:927-935.
    >> Share

  130. MCALPINE K, Lavallee LT, Stacey D, Moodley P, et al
    Development and Acceptability Testing of a Patient Decision Aid for Urinary Diversion with Radical Cystectomy.
    J Urol. 2019;202:1001-1007.
    >> Share

    October 2019
  131. LOTAN Y
    Re: Evaluation of the Fluorescence In Situ Hybridization Test to Predict Recurrence and/or Progression of Disease after bacillus Calmette-Guerin for Primary High Grade Nonmuscle Invasive Bladder Cancer: Results from a Prospective Multicenter Trial.
    J Urol. 2019 Oct 25:101097JU0000000000000625. doi: 10.1097/JU.0000000000000625.
    >> Share

  132. MONTORSI F, Moschini M, Briganti A
    Re: Evaluation of the Fluorescence In Situ Hybridization Test to Predict Recurrence and/or Progression of Disease after bacillus Calmette-Guerin for Primary High Grade Nonmuscle Invasive Bladder Cancer: Results from a Prospective Multicenter Trial.
    J Urol. 2019 Oct 24:101097JU0000000000000624. doi: 10.1097/JU.0000000000000624.
    >> Share

  133. CHANG SS
    Re: Occupation and Bladder Cancer Phenotype: Identification of Workplace Patterns That Increase the Risk of Advanced Disease beyond Overall Incidence.
    J Urol. 2019 Oct 16:101097JU0000000000000599. doi: 10.1097/JU.0000000000000599.
    >> Share

  134. RITCH CR, Velasquez MC, Kwon D, Becerra MF, et al
    Utility and Validation of the AUA/SUO Risk Grouping for Non-muscle Invasive Bladder Cancer in a Contemporary Cohort.
    J Urol. 2019 Oct 14:101097JU0000000000000593. doi: 10.1097/JU.0000000000000593.
    >> Share

  135. LABBATE C, Werntz RP, Adamic B, Steinberg GD, et al
    The Impact of Omission of Intraoperative Frozen Section Prior to Orthotopic Neobladder Reconstruction.
    J Urol. 2019;202:763-769.
    >> Share

  136. SINGLA N
    Editorial Comment.
    J Urol. 2019;202:688.
    >> Share

  137. SEFIK E, Bozkurt IH, Basmaci I, Celik S, et al
    Re: Perioperative Oral Nutrition Supplementation Reduces Prevalence of Sarcopenia following Radical Cystectomy: Results of a Prospective Randomized Controlled Trial.
    J Urol. 2019;202:819.
    >> Share

  138. LUO Y, Wang X, Xiao Y
    Re: Perioperative Oral Nutrition Supplementation Reduces Prevalence of Sarcopenia following Radical Cystectomy: Results of a Prospective Randomized Controlled Trial.
    J Urol. 2019;202:819-820.
    >> Share

    September 2019
  139. LIEM EI, Oddens JR, Vernooij R, Li R, et al
    The Role of Fluorescence in Situ Hybridization for Predicting Recurrence after Adjuvant Bacillus Calmette-Guerin in Intermediate- and High-Risk Non-muscle Invasive Bladder Cancer Patients: A Systematic Review and Meta-Analysis of Individual Patient Da
    J Urol. 2019 Sep 24:101097JU0000000000000566. doi: 10.1097/JU.0000000000000566.
    >> Share

  140. GRIEBLING TL
    Re: The Feasibility and Safety of Reproductive Organ Preserving Radical Cystectomy for Elderly Female Patients with Muscle-Invasive Bladder Cancer: A Retrospective Propensity Score-Matched Study.
    J Urol. 2019 Sep 18:101097JU0000000000000559. doi: 10.1097/JU.0000000000000559.
    >> Share

  141. GRIEBLING TL
    Re: Disparities in Bladder Cancer Treatment and Survival amongst Elderly Patients with a Pre-Existing Mental Illness.
    J Urol. 2019 Sep 18:10109701JU00005857524193298.
    >> Share

  142. CHANG SS
    Re: Prognostic Significance of Lymphatic, Vascular and Perineural Invasion for Bladder Cancer Patients Treated by Radical Cystectomy.
    J Urol. 2019 Sep 18:10109701JU0000585772800505.
    >> Share

  143. GRIEBLING TL
    Re: High-Precision Bladder Cancer Irradiation in the Elderly: Clinical Results for a Plan-of-the-Day Integrated Boost Technique with Image Guidance Using Lipiodol Markers.
    J Urol. 2019 Sep 18:10109701JU00005857643430962.
    >> Share

  144. GRIEBLING TL
    Re: Cost-Effectiveness of Surveillance Schedules in Older Adults with Non-Muscle-Invasive Bladder Cancer.
    J Urol. 2019 Sep 18:10109701JU00005857564955687.
    >> Share

  145. GRIEBLING TL
    Re: Evaluation of Cause of Death after Radical Cystectomy for Patients with Bladder Cancer: The Impact of Age at the Time of Surgery.
    J Urol. 2019 Sep 18:10109701JU000058576026685.
    >> Share

  146. CHANG SS
    Re: Cost-Effectiveness of Pembrolizumab in Second-Line Advanced Bladder Cancer.
    J Urol. 2019 Sep 18:10109701JU000058576872427.
    >> Share

  147. MOREY AF
    Re: Dual Prosthetic Implantation after Radical Cystoprostatectomy and Neobladder: Outcomes of the Inflatable Penile Prosthesis and Artificial Urinary Sphincter in Bladder Cancer Survivors.
    J Urol. 2019 Sep 13:101097JU0000000000000549. doi: 10.1097/JU.0000000000000549.
    >> Share

  148. ATALA A
    Re: Bladder Cancer Extracellular Vesicles Drive Tumorigenesis by Inducing the Unfolded Protein Response in Endoplasmic Reticulum of Nonmalignant Cells.
    J Urol. 2019 Sep 12:10109701JU00005851520364998.
    >> Share

  149. LAGUNA MP
    Re: Clonal Relatedness and Mutational Differences between Upper Tract and Bladder Urothelial Carcinoma.
    J Urol. 2019;202:456-457.
    >> Share

  150. KHANNA A, Saarela O, Lawson K, Finelli A, et al
    Hospital Quality Metrics for Radical Cystectomy: Disease Specific and Correlated to Mortality Outcomes.
    J Urol. 2019;202:490-497.
    >> Share

    August 2019
  151. BJURLIN MA, Nielsen ME
    Editorial Comment.
    J Urol. 2019;202:246.
    >> Share

  152. RICHARD PO, Bashir S, Riverin BD, Alibhai SMH, et al
    Risk of Bone Fractures Following Urinary Intestinal Diversion: A Population Based Study.
    J Urol. 2019;202:319-325.
    >> Share

    July 2019
  153. CHANG SS
    Re: Tumor Evolution and Drug Response in Patient-Derived Organoid Models of Bladder Cancer.
    J Urol. 2019 Jul 31:10109701JU00005794560657170.
    >> Share

  154. CHANG SS
    Re: Curcumin as Treatment for Bladder Cancer: A Preclinical Study of Cyclodextrin-Curcumin Complex and BCG as Intravesical Treatment in an Orthotopic Bladder Cancer Rat Model.
    J Urol. 2019 Jul 31:101097JU0000000000000479. doi: 10.1097/JU.0000000000000479.
    >> Share

  155. CHANG SS
    Re: Monitoring Treatment Response and Metastatic Relapse in Advanced Bladder Cancer by Liquid Biopsy Analysis.
    J Urol. 2019 Jul 31:10109701JU00005794608369953.
    >> Share

  156. ATALA A
    Re: Mouse and Human Urothelial Cancer Organoids: A Tool for Bladder Cancer Research.
    J Urol. 2019 Jul 9:10109701JU000057698421354.
    >> Share

  157. CHANG SS
    Re: Population-Based Assessment of Racial/Ethnic Differences in Utilization of Radical Cystectomy for Patients Diagnosed with Bladder Cancer.
    J Urol. 2019 Jul 9:10109701JU0000576988055492.
    >> Share

  158. FILIPPOU P, Smith AB
    Editorial Comment.
    J Urol. 2019;202:89.
    >> Share

    June 2019
  159. KUROIWA K, Inokuchi J, Nishiyama H, Kojima T, et al
    Impact of Previous, Simultaneous or Subsequent Bladder Cancer on Prognosis after Radical Nephroureterectomy for Upper Urinary Tract Urothelial Carcinoma.
    J Urol. 2019 Jun 28:101097JU0000000000000422. doi: 10.1097/JU.0000000000000422.
    >> Share

  160. RAVVAZ K, Weissert JA, Downs TM
    American Urological Association Non-muscle Invasive Bladder Cancer Risk Model Validation: Should patient age be added to the risk model?
    J Urol. 2019 Jun 12:101097JU0000000000000389. doi: 10.1097/JU.0000000000000389.
    >> Share

  161. CHANG SS
    Re: Predicting Grade and Stage at Cystoscopy in Newly Presenting Bladder Cancers-A Prospective Double-Blind Clinical Study.
    J Urol. 2019 Jun 10:10109701JU00005691889046242.
    >> Share

  162. CHANG SS
    Re: Disseminated Mycobacterium bovis Infection Post-Kidney Transplant following Remote Intravesical BCG Therapy for Bladder Cancer.
    J Urol. 2019 Jun 10:101097JU0000000000000381. doi: 10.1097/JU.0000000000000381.
    >> Share

  163. WEI L, Hussein AA, Ma Y, Azabdaftari G, et al
    Accurate Quantification of Residual Cancer Cells in Pelvic Washing Reveals Association with Cancer Recurrence Following Robot-Assisted Radical Cystectomy.
    J Urol. 2019;201:1105-1114.
    >> Share

    May 2019
  164. WESTERGREN DO, Gardmark T, Lindhagen L, Chau A, et al
    A Nationwide Population Based Analysis of Organ-Confined Muscle-Invasive Bladder Cancer Patients Not Receiving Curative Intent Therapy in Sweden from 1997 to 2014.
    J Urol. 2019 May 30:101097JU0000000000000350. doi: 10.1097/JU.0000000000000350.
    >> Share

  165. LOTAN Y, Inman BA, Davis LG, Kassouf W, et al
    Evaluation of the UroVysion Test to Predict Recurrence and/or Progression of Disease After BCG for Primary High Grade Non-Muscle Invasive Bladder Cancer: Results from a Prospective Multicenter Trial.
    J Urol. 2019 May 23:101097JU0000000000000355. doi: 10.1097/JU.0000000000000355.
    >> Share

  166. MORERA DS, Lahorewala SS, Belew D, Ghosh S, et al
    Clinical parameters outperform molecular subtypes for predicting outcome in bladder cancer: Results from multiple cohorts including TCGA.
    J Urol. 2019 May 21:101097JU0000000000000351. doi: 10.1097/JU.0000000000000351.
    >> Share

  167. CHANG SS
    Re: Discrepancies in Staging, Treatment, and Delays to Treatment May Explain Disparities in Bladder Cancer Outcomes: An Update from the National Cancer Data Base (2004-2013).
    J Urol. 2019 May 8:10109701JU000055962335906.
    >> Share

  168. CHANG SS
    Re: Characterization of Late Recurrence after Radical Cystectomy in a Large Multicenter Cohort of Bladder Cancer Patients.
    J Urol. 2019 May 8:10109701JU00005596222828385.
    >> Share

  169. CHANG SS
    Re: Extended versus Limited Lymph Node Dissection in Bladder Cancer Patients Undergoing Radical Cystectomy: Survival Results from a Prospective, Randomized Trial.
    J Urol. 2019 May 8:101097JU0000000000000332. doi: 10.1097/JU.0000000000000332.
    >> Share

  170. MENG MV, Gschwend JE, Shore N, Grossfeld GD, et al
    Emerging Immunotherapy Options for BCG-unresponsive Non-muscle-invasive Bladder Cancer.
    J Urol. 2019 May 1:101097JU0000000000000297. doi: 10.1097/JU.0000000000000297.
    >> Share

  171. WOLDU SL
    Editorial Comment.
    J Urol. 2019;201:901.
    >> Share

  172. METCALF M, Glazyrine V, Glavin K, Dahlgren A, et al
    The Feasibility of a Health Care Application in the Treatment of Patients Undergoing Radical Cystectomy.
    J Urol. 2019;201:902-908.
    >> Share

  173. ROTH B, Furrer MA, Giannakis I, Vartolomei MD, et al
    Positive Pre-cystectomy Biopsies of the Prostatic Urethra or Bladder Neck Do Not Necessarily Preclude Orthotopic Bladder Substitution.
    J Urol. 2019;201:909-915.
    >> Share

    April 2019
  174. ABUFARAJ M, Tabung FK, Shariat SF, Moschini M, et al
    Association between inflammatory potential of diet and bladder cancer risk:Results from three US prospective cohort studies.
    J Urol. 2019 Apr 22:101097JU0000000000000279. doi: 10.1097/JU.0000000000000279.
    >> Share

    March 2019
  175. CHANG SS
    Re: Genomic Differences between "Primary" and "Secondary" Muscle-Invasive Bladder Cancer as a Basis for Disparate Outcomes to Cisplatin-Based Neoadjuvant Chemotherapy.
    J Urol. 2019 Mar 29:10109701JU0000557728168538.
    >> Share

  176. CHANG SS
    Re: Contemporary Treatment Patterns and Outcomes of Sarcomatoid Bladder Cancer.
    J Urol. 2019 Mar 29:101097JU0000000000000252. doi: 10.1097/JU.0000000000000252.
    >> Share

  177. CHANG SS
    Re: Mutational Patterns in Chemotherapy Resistant Muscle-Invasive Bladder Cancer.
    J Urol. 2019 Mar 29:10109701JU000055772739723.
    >> Share

  178. CHANG SS
    Re: Safety and Efficacy of Temsirolimus as Second Line Treatment for Patients with Recurrent Bladder Cancer.
    J Urol. 2019 Mar 13:10109701JU000055464194059.
    >> Share

  179. CHANG SS
    Re: Partial Bladder Boost Using Lipiodol Marking during Image-Guided Radiotherapy for Bladder Cancer.
    J Urol. 2019 Mar 13:101097JU0000000000000218. doi: 10.1097/JU.0000000000000218.
    >> Share

  180. GRIEBLING TL
    Re: Comparative Safety of Pioglitazone versus Clinically Meaningful Treatment Alternatives Concerning the Risk of Bladder Cancer in Older US Adults with Type 2 Diabetes.
    J Urol. 2019 Mar 13:10109701JU00005546361960937.
    >> Share

  181. GRIEBLING TL
    Re: Outcomes of Radiosensitisation in Elderly Patients with Advanced Bladder Cancer.
    J Urol. 2019 Mar 13:10109701JU00005546347386712.
    >> Share

  182. GRIEBLING TL
    Re: Real-World Effectiveness of Chemotherapy in Elderly Patients with Metastatic Bladder Cancer in the United States.
    J Urol. 2019 Mar 13:10109701JU0000554635814908.
    >> Share

  183. WINTERS BR, Wen L, Holt SK, Dash A, et al
    Does the diagnosis of bladder cancer lead to higher rates of smoking cessation? Findings from the Medicare Health Outcomes Survey.
    J Urol. 2019 Mar 5:101097JU0000000000000206. doi: 10.1097/JU.0000000000000206.
    >> Share

  184. LEO MC, Gilbert SM, Wendel CS, Krouse RS, et al
    Development of a goal elicitation measure to support bladder cancer patients' choice about urinary diversion.
    J Urol. 2019 Mar 5:101097JU0000000000000203. doi: 10.1097/JU.0000000000000203.
    >> Share

  185. CHANG SS
    Re: Effect of Intravesical Instillation of Gemcitabine vs Saline Immediately following Resection of Suspected Low-Grade Non-Muscle-Invasive Bladder Cancer on Tumor Recurrence: .
    J Urol. 2019;201:442.
    >> Share

  186. CHANG SS
    Re: Human Epidermal Growth Factor Receptor 2 Expression is More Important than bacillus Calmette Guerin Treatment in Predicting the Outcome of T1G3 Bladder Cancer.
    J Urol. 2019;201:441-442.
    >> Share

  187. CHANG SS
    Re: Assessing Cancer Progression and Stable Disease after Neoadjuvant Chemotherapy for Organ-Confined Muscle-Invasive Bladder Cancer.
    J Urol. 2019;201:441.
    >> Share

  188. PARKER DC, Abboud MA, Patel SG
    Is Routine Removal of the Ovaries Advisable during Radical Cystectomy?
    J Urol. 2019;201:455-456.
    >> Share

    February 2019
  189. CHANG SS
    Re: Predicting Local Failure after Radical Cystectomy in Patients with Bladder Cancer: .
    J Urol. 2019 Feb 8. doi: 10.1097/JU.0000000000000166.
    >> Share

  190. CHANG SS
    Re: National Comprehensive Cancer Network Recommendations on Molecular Profiling of Advanced Bladder Cancer.
    J Urol. 2019 Feb 8. doi: 10.1097/01.JU.0000554054.35801.
    >> Share

  191. CHANG SS
    Re: Preclinical Evaluation of Intravesical Cisplatin Nanoparticles for Non-Muscle-Invasive Bladder Cancer.
    J Urol. 2019 Feb 8. doi: 10.1097/01.JU.0000554055.35801.
    >> Share

  192. GRIEBLING TL
    Re: Impact of Psychiatric Illness on Decreased Survival in Elderly Patients with Bladder Cancer in the United States.
    J Urol. 2019 Feb 7. doi: 10.1097/JU.0000000000000162.
    >> Share

  193. GRIEBLING TL
    Re: Comparing Survival Outcomes and Costs Associated with Radical Cystectomy and Trimodal Therapy for Older Adults with Muscle-Invasive Bladder Cancer.
    J Urol. 2019 Feb 7. doi: 10.1097/01.JU.0000553996.66966.
    >> Share

  194. GRIEBLING TL
    Re: The Challenges of Bacillus of Calmette-Guerin (BCG) Therapy for High Risk Non Muscle Invasive Bladder Cancer Treatment in Older Patients.
    J Urol. 2019 Feb 7. doi: 10.1097/01.JU.0000553995.59343.
    >> Share

  195. ATALA A
    Re: Identification of MicroR-106b as a Prognostic Biomarker of p53-Like Bladder Cancers by ActMiR.
    J Urol. 2019;201:231.
    >> Share

  196. CHANG SS
    Re: Analysis of T1 Bladder Cancer on Biopsy and Transurethral Resection Specimens: .
    J Urol. 2019;201:225-226.
    >> Share

  197. WANG DS
    Re: A Prospective Randomized Pilot Study Evaluating an ERAS Protocol versus a Standard Protocol for Patients Treated with Radical Cystectomy and Urinary Diversion for Bladder Cancer.
    J Urol. 2019 Feb 1. doi: 10.1097/JU.0000000000000154.
    >> Share

    January 2019
  198. EBRAHIMI H, Amini E, Pishgar F, Moghaddam SS, et al
    Global, Regional, and National Burden of Bladder Cancer, 1990 - 2016: Results from the Global Burden of Disease Study 2016.
    J Urol. 2019 Jan 25. doi: 10.1097/JU.0000000000000025.
    >> Share

  199. CHANG SS
    Re: Long-Term Survival Outcomes with Intravesical Nanoparticle Albumin-Bound Paclitaxel for Recurrent Non-Muscle-Invasive Bladder Cancer after Previous Bacillus Calmette-Guerin Therapy.
    J Urol. 2019 Jan 15. doi: 10.1097/JU.0000000000000097.
    >> Share

  200. CHANG SS
    Re: Next-Generation Sequencing of Nonmuscle Invasive Bladder Cancer Reveals Potential Biomarkers and Rational Therapeutic Targets.
    J Urol. 2019 Jan 15. doi: 10.1097/01.JU.0000553308.83315.
    >> Share

  201. ATALA A
    Re: LNMAT1 Promotes Lymphatic Metastasis of Bladder Cancer via CCL2 Dependent Macrophage Recruitment.
    J Urol. 2019 Jan 15. doi: 10.1097/01.JU.0000553307.75692.
    >> Share

  202. CHANG SS
    Re: Pathologic Response in Patients Receiving Neoadjuvant Chemotherapy for Muscle-Invasive Bladder Cancer: Is Therapeutic Effect Owing to Chemotherapy or TURBT?
    J Urol. 2019;201:30.
    >> Share

  203. CHANG SS
    Re: Adjuvant Sandwich Chemotherapy plus Radiotherapy vs Adjuvant Chemotherapy Alone for Locally Advanced Bladder Cancer after Radical Cystectomy: A Randomized Phase 2 Trial.
    J Urol. 2019;201:29.
    >> Share

  204. KIMURA S, Mari A, Foerster B, Abufaraj M, et al
    Prognostic Value of Concomitant Carcinoma In Situ in the Radical Cystectomy Specimen: A Systematic Review and Meta-Analysis.
    J Urol. 2019;201:46-53.
    >> Share

    December 2018
  205. XUE W, Yang L, Wei Q
    Re: Comparison of Pathological Stage in Patients Treated with and without Neoadjuvant Chemotherapy for High Risk Upper Tract Urothelial Carcinoma: R. S. Liao, M. Gupta, Z. R. Schwen, H. D. Patel, M. Kates, M. H. Johnson, N. M. Hahn, D. McConkey, T. J.
    J Urol. 2018;200:1378-1379.
    >> Share

    November 2018
  206. ATALA A
    Re: An FGFR3/MYC Positive Feedback Loop Provides New Opportunities for Targeted Therapies in Bladder Cancers.
    J Urol. 2018;200:947-948.
    >> Share

  207. CHANG SS
    Re: Analysis of T1 Bladder Cancer on Biopsy and Transurethral Resection Specimens: Comparison and Ranking of T1 Quantification Approaches to Predict Progression to Muscularis Propria Invasion.
    J Urol. 2018;200:942-943.
    >> Share

  208. GRIEBLING TL
    Re: Curative Treatment for Muscle Invasive Bladder Cancer in Elderly Patients: A Systematic Review.
    J Urol. 2018;200:922.
    >> Share

    October 2018
  209. PEYTON CC, Henriksen C, Reich RR, Azizi M, et al
    Estimating Minimally Important Differences for the Bladder Cancer Index Using Distribution- and Anchor-Based Approaches.
    J Urol. 2018 Oct 17. pii: S0022-5347(18)43986-9. doi: 10.1016/j.juro.2018.
    >> Share

  210. FRANSEN VAN DE PUTTE EE, Pos F, Doodeman B, van Rhijn BWG, et al
    Concurrent radiotherapy and panitumumab after lymph node dissection and induction chemotherapy for invasive bladder cancer.
    J Urol. 2018 Oct 12. pii: S0022-5347(18)43985-7. doi: 10.1016/j.juro.2018.
    >> Share

  211. CHANG SS
    Re: Results of a Randomised Controlled Trial Comparing Intravesical Chemohyperthermia with Mitomycin C versus bacillus Calmette-Guerin for Adjuvant Treatment of Patients with Intermediate- and High-Risk Non-Muscle-Invasive Bladder Cancer.
    J Urol. 2018;200:696-697.
    >> Share

    September 2018
  212. CHANG SS
    Re: Contemporary Use Trends and Survival Outcomes in Patients Undergoing Radical Cystectomy or Bladder-Preservation Therapy for Muscle-Invasive Bladder Cancer.
    J Urol. 2018;200:497.
    >> Share

  213. CHANG SS
    Re: Association between Number of Endoscopic Resections and Utilization of bacillus Calmette-Guerin Therapy for Patients with High-Grade, Non-Muscle-Invasive Bladder Cancer.
    J Urol. 2018;200:496-497.
    >> Share

  214. WHITSON JM
    Editorial Comment.
    J Urol. 2018;200:539-540.
    >> Share

    August 2018
  215. FEUERSTEIN MA
    Editorial Comment.
    J Urol. 2018;200:290.
    >> Share

  216. PATEL S, Cookson MS
    Editorial Comment.
    J Urol. 2018;200:290-291.
    >> Share

  217. ZARGAR-SHOSHTARI K, Sexton WJ
    Re: Stenting Prior to Cystectomy is an Independent Risk Factor for Upper Urinary Tract Recurrence: B. Kiss, M. A. Furrer, P. Y. Wuethrich, F. C. Burkhard, G. N. Thalmann and B. Roth J Urol 2017;198:1263-1268.
    J Urol. 2018;200:457-458.
    >> Share

  218. HAMILTON-REEVES JM, Stanley A, Bechtel MD, Yankee TM, et al
    Perioperative Immunonutrition Modulates Inflammatory Response after Radical Cystectomy: Results of a Pilot Randomized Controlled Clinical Trial.
    J Urol. 2018;200:292-301.
    >> Share

    July 2018
  219. HAIFLER M
    Editorial Comment.
    J Urol. 2018;200:59-60.
    >> Share

  220. FILSON CP
    Editorial Comment.
    J Urol. 2018;200:59.
    >> Share

  221. MEEKS JJ, Glaser AP
    Editorial Comment.
    J Urol. 2018;200:60.
    >> Share

    June 2018
  222. DOWNS TM, Weissert JA, Ravvaz K
    Can we improve non-muscle-invasive bladder cancer (NMIBC) guideline adherence with smarter risk-stratification?
    J Urol. 2018 Jun 12. pii: S0022-5347(18)43357-5. doi: 10.1016/j.juro.2018.
    >> Share

  223. AUDENET F, Waingankar N, Ferket BS, Niglio SA, et al
    Effectiveness of transurethral resection (TUR) plus systemic chemotherapy as definitive treatment for muscle-invasive bladder cancer (MIBC) in population-level data.
    J Urol. 2018 Jun 4. pii: S0022-5347(18)43313-7. doi: 10.1016/j.juro.2018.
    >> Share

    May 2018
  224. MAZZA P, Moran GW, Li G, Robins DJ, et al
    Conservative Management Following Clinical Complete Response to Neoadjuvant Chemotherapy for Muscle-Invasive Bladder Cancer: Contemporary Outcomes of a Multi-Institutional Cohort Study.
    J Urol. 2018 May 19. pii: S0022-5347(18)43234-X. doi: 10.1016/j.juro.2018.
    >> Share

  225. MAKELA VJ, Kotsar A, Tammela TL, Murtola TJ, et al
    Bladder cancer survival in men using 5-alpha-reductase inhibitors.
    J Urol. 2018 May 3. pii: S0022-5347(18)43085-6. doi: 10.1016/j.juro.2018.
    >> Share

  226. ATALA A
    Re: Evasion of Immunosurveillance by Genomic Alterations of PPARgamma/RXRalpha in Bladder Cancer.
    J Urol. 2018;199:1115-1116.
    >> Share

  227. CHANG SS
    Re: Definitions, End Points, and Clinical Trial Designs for Non-Muscle-Invasive Bladder Cancer: Recommendations from the International Bladder Cancer Group.
    J Urol. 2018;199:1111-1112.
    >> Share

  228. CHANG SS
    Re: Intravesical rAd-IFNalpha/Syn3 for Patients with High-Grade, bacillus Calmette-Guerin-Refractory or Relapsed Non-Muscle-Invasive Bladder Cancer: A Phase II Randomized Study.
    J Urol. 2018;199:1110-1111.
    >> Share

    April 2018
  229. CHANG SS
    Re: Phase III, Double-Blind, Randomized Trial that Compared Maintenance Lapatinib versus Placebo after First-Line Chemotherapy in Patients with Human Epidermal Growth Factor Receptor 1/2-Positive Metastatic Bladder Cancer.
    J Urol. 2018;199:891-892.
    >> Share

  230. CHANG SS
    Re: Comparative Effectiveness of Treatment Strategies for Bladder Cancer with Clinical Evidence of Regional Lymph Node Involvement.
    J Urol. 2018;199:891-892.
    >> Share

    March 2018
  231. KAPADIA AA, Acevedo AM, Liu JJ, Garzotto M, et al
    Unconventional Bladder Preservation: Factors predicting Failure to Receive Definitive Surgery following Chemotherapy for Non-metastatic Muscle Invasive Bladder Cancer within the National Cancer Database.
    J Urol. 2018 Mar 15. pii: S0022-5347(18)42581-5. doi: 10.1016/j.juro.2018.
    >> Share

  232. PERLIS N, Krahn MD, Boehme KE, Alibhai SM, et al
    The Bladder Utility Symptom Scale (BUSS): A Novel Patient-Reported Outcome Instrument in Bladder Cancer.
    J Urol. 2018 Mar 9. pii: S0022-5347(18)42498-6. doi: 10.1016/j.juro.2018.
    >> Share

    February 2018
  233. UHLIG A, Amir Hosseini AS, Simon J, Lotz J, et al
    Gender-specific differences in disease-free, cancer-specific and overall survival after radical cystectomy for bladder cancer: a systematic review and meta-analysis.
    J Urol. 2018 Feb 22. pii: S0022-5347(18)39380-7. doi: 10.1016/j.juro.2017.
    >> Share

  234. CHANG SS
    Re: Safety and Efficacy of Durvalumab (MEDI4736), an Anti-Programmed Cell Death Ligand-1 Immune Checkpoint Inhibitor, in Patients with Advanced Urothelial Bladder Cancer.
    J Urol. 2018;199:341-342.
    >> Share

  235. CHANG SS
    Re: The Impact of Re-Transurethral Resection on Clinical Outcomes in a Large Multicentre Cohort of Patients with T1 High-Grade/Grade 3 Bladder Cancer Treated with bacille Calmette-Guerin.
    J Urol. 2018;199:340-342.
    >> Share

    January 2018
  236. ZARGAR H, Shah JB, van Rhijn BW, Daneshmand S, et al
    Neoadjuvant dose dense MVAC versus GC in patients with cT3-4aN0M0 bladder cancer treated with radical cystectomy.
    J Urol. 2018 Jan 9. pii: S0022-5347(18)30036-3. doi: 10.1016/j.juro.2017.
    >> Share

  237. NIWA N, Kikuchi E, Matsumoto K, Kosaka T, et al
    Purified protein derivative skin test prior to bacillus Calmette-Guerin therapy may have therapeutic impact in patients with non-muscle-invasive bladder cancer.
    J Urol. 2018 Jan 4. pii: S0022-5347(18)30006-5. doi: 10.1016/j.juro.2017.
    >> Share

  238. CHANG SS
    Re: Increasing Age is Not Associated with Toxicity Leading to Discontinuation of Treatment in Patients with Urothelial Non-Muscle-Invasive Bladder Cancer Randomised to Receive 3 Years of Maintenance bacille Calmette-Guerin: Results from European Organ
    J Urol. 2018;199:26.
    >> Share

  239. CHANG SS
    Re: Challenges in Pathologic Staging of Bladder Cancer: Proposals for Fresh Approaches of Assessing Pathologic Stage in Light of Recent Studies and Observations Pertaining to Bladder Histoanatomic Variances.
    J Urol. 2018;199:25-26.
    >> Share

    December 2017
  240. CHANG SS
    Re: Propensity Score Analysis of Radical Cystectomy versus Bladder-Sparing Trimodal Therapy in the Setting of a Multidisciplinary Bladder Cancer Clinic.
    J Urol. 2017;198:1208.
    >> Share

  241. DANESHMAND S, Patel S, Lotan Y, Pohar K, et al
    Efficacy and Safety of Blue Light Flexible Cystoscopy With Hexaminolevulinate (Hal) in the Surveillance of Bladder Cancer: A Phase Iii, Comparative, Multi-Center Study.
    J Urol. 2017 Dec 1. pii: S0022-5347(17)78004-4. doi: 10.1016/j.juro.2017.
    >> Share

    November 2017
  242. CASILLA-LENNON MM, Choi SK, Deal AM, Bensen JT, et al
    Financial Toxicity in Bladder Cancer Patients- Reasons for Delay in Care and Effect on Quality of Life.
    J Urol. 2017 Nov 16. pii: S0022-5347(17)77917-7. doi: 10.1016/j.juro.2017.
    >> Share

  243. KOUMPAN Y, Jaeger M, Mizubuti GB, Tanzola R, et al
    Spinal Anesthesia is Associated with Lower Recurrence Rates after Resection of Non-Muscle Invasive Bladder Cancer.
    J Urol. 2017 Nov 14. pii: S0022-5347(17)77909-8. doi: 10.1016/j.juro.2017.
    >> Share

  244. ATALA A
    Re: ARF Confers a Context-Dependent Response to Chemotherapy in Muscle-Invasive Bladder Cancer.
    J Urol. 2017;198:985.
    >> Share

  245. ATALA A
    Re: Loss of Tumor Suppressor KDM6A Amplifies PRC2-Regulated Transcriptional Repression in Bladder Cancer and Can be Targeted through Inhibition of EZH2.
    J Urol. 2017;198:984-985.
    >> Share

  246. ATALA A
    Re: Profiling of Long Non-Coding RNAs Identifies LINC00958 and LINC01296 as Candidate Oncogenes in Bladder Cancer.
    J Urol. 2017;198:983-985.
    >> Share

  247. CHANG SS
    Re: Refraining from Smoking for 15 Years or More Reduced the Risk of Tumor Recurrence in Non-Muscle Invasive Bladder Cancer Patients.
    J Urol. 2017;198:979-980.
    >> Share

  248. CHANG SS
    Re: Anti-Inflammatory Use May Not Negatively Impact Oncologic Outcomes following Intravesical BCG for High-Grade Non-Muscle-Invasive Bladder Cancer.
    J Urol. 2017;198:978-980.
    >> Share

    October 2017
  249. WALLACE E, Higuchi R, Satya M, McCann L, et al
    Development of a 90-minute integrated non-invasive urinary assay for bladder cancer detection.
    J Urol. 2017 Oct 20. pii: S0022-5347(17)77760-9. doi: 10.1016/j.juro.2017.
    >> Share

  250. RYAN S, Serrell EC, Karabon P, Mills G, et al
    The Association Between Mortality and Distance to Treatment Facility in Patients with Muscle Invasive Bladder Cancer.
    J Urol. 2017 Oct 10. pii: S0022-5347(17)77715-4. doi: 10.1016/j.juro.2017.
    >> Share

    September 2017
  251. CHANG SS
    Re: Prediction Model for Recurrence Probabilities after Intravesical Chemotherapy in Patients with Intermediate-Risk Non-Muscle-Invasive Bladder Cancer, Including External Validation.
    J Urol. 2017;198:482-483.
    >> Share

  252. CHANG SS
    Re: New Strategies in Bladder Cancer: A Second Coming for Immunotherapy.
    J Urol. 2017;198:482-483.
    >> Share

  253. SANCHEZ A, Wszolek MF, Niemierko A, Clayman RH, et al
    Incidence, clinicopathologic risk factors, management and outcomes of non-muscle invasive recurrences after complete response to tri-modality therapy for muscle-invasive bladder cancer.
    J Urol. 2017 Sep 1. pii: S0022-5347(17)77426-5. doi: 10.1016/j.juro.2017.
    >> Share

    August 2017
  254. NARAYAN VM, Adejoro O, Schwartz I, Ziegelmann M, et al
    The Prevalence and Impact of Urinary Marker Testing in Patients with Bladder Cancer.
    J Urol. 2017 Aug 28. pii: S0022-5347(17)77411-3. doi: 10.1016/j.juro.2017.
    >> Share

  255. SMITH ZL, Johnson SC, Golan S, McGinnis JR, et al
    Fistulous complications following radical cystectomy for bladder cancer: analysis of a large modern cohort.
    J Urol. 2017 Aug 28. pii: S0022-5347(17)77409-5. doi: 10.1016/j.juro.2017.
    >> Share

  256. HURLE R, Lazzeri M, Vanni E, Lughezzani G, et al
    Active surveillance for low-risk Non-Muscle Invasive Bladder Cancer (NMIBC): a confirmatory and resource consumption study from Bladder cancer Italian Active Surveillance (BIAS) project.
    J Urol. 2017 Aug 25. pii: S0022-5347(17)77391-0. doi: 10.1016/j.juro.2017.
    >> Share

  257. ATALA A
    Re: Mg(II)-Catechin Nanoparticles Delivering siRNA Targeting EIF5A2 Inhibit Bladder Cancer Cell Growth In Vitro and In Vivo.
    J Urol. 2017;198:258-259.
    >> Share

  258. CHANG SS
    Re: Papillary Recurrence of Bladder Cancer at First Evaluation after Induction Bacillus Calmette-Guerin Therapy: Implication for Clinical Trial Design.
    J Urol. 2017;198:255.
    >> Share

    July 2017
  259. CHANG SS
    Re: Phase II Drug-Metabolizing Polymorphisms and Smoking Predict Recurrence of Non-Muscle-Invasive Bladder Cancer: A Gene-Smoking Interaction.
    J Urol. 2017;198:40.
    >> Share

  260. CHANG SS
    Re: EORTC Nomograms and Risk Groups for Predicting Recurrence, Progression, and Disease-Specific and Overall Survival in Non-Muscle-Invasive Stage Ta-T1 Urothelial Bladder Cancer Patients Treated with 1-3 Years of Maintenance Bacillus Calmette-Guerin.
    J Urol. 2017;198:39-41.
    >> Share

    June 2017
  261. ARK JT, Alvarez JR, Koyama T, Bassett JC, et al
    Variation in the diagnostic evaluation among persons with hematuria: influence of gender, race, and risk factors for bladder cancer.
    J Urol. 2017 Jun 24. pii: S0022-5347(17)76746-8. doi: 10.1016/j.juro.2017.
    >> Share

  262. LAGUNA MP
    Re: Oncologic Outcomes of Kidney-Sparing Surgery versus Radical Nephroureterectomy for Upper Tract Urothelial Carcinoma: A Systematic Review by the EAU Non-Muscle Invasive Bladder Cancer Guidelines Panel.
    J Urol. 2017;197:1437-1438.
    >> Share

    April 2017
  263. CHANG SS, Bochner BH, Chou R, Dreicer R, et al
    Treatment of Non-Metastatic Muscle-Invasive Bladder Cancer: AUA/ASCO/ASTRO/SUO Guideline.
    J Urol. 2017 Apr 26. pii: S0022-5347(17)57836-2. doi: 10.1016/j.juro.2017.
    >> Share

  264. RAVVAZ K, Walz ME, Weissert JA, Downs TM, et al
    Predicting non-muscle invasive bladder cancer recurrence and progression in a US population.
    J Urol. 2017 Apr 19. pii: S0022-5347(17)54785-0. doi: 10.1016/j.juro.2017.
    >> Share

    March 2017
  265. KIM JH, Chung BI
    Re: Suppressed Recurrent Bladder Cancer after Androgen Suppression with Androgen Deprivation Therapy or 5alpha-Reductase Inhibitor: M. Shiota, K. Kiyoshima, A. Yokomizo, A. Takeuchi, E. Kashiwagi, T. Dejima, R. Takahashi, J. Inokuchi, K. Tatsugami and
    J Urol. 2017 Mar 29. pii: S0022-5347(17)30226-4. doi: 10.1016/j.juro.2017.
    >> Share

  266. BOEHM BE, Cornell JE, Wang H, Mukherjee N, et al
    Efficacy of Bacillus Calmette-guerin Strains for the Treatment of non-muscle Invasive Bladder Cancer: a Systematic Review and Network Meta-analysis.
    J Urol. 2017 Mar 9. pii: S0022-5347(17)39246-7. doi: 10.1016/j.juro.2017.
    >> Share

  267. TOBERT CM, Hamilton-Reeves JM, Norian LA, Hung C, et al
    The Emerging Impact of Malnutrition on Surgical Patients: Literature Review and Potential Implications on Cystectomy for Bladder Cancer.
    J Urol. 2017 Mar 9. pii: S0022-5347(17)39247-9. doi: 10.1016/j.juro.2017.
    >> Share

  268. CHANG SS
    Re: Benefits of Adjuvant Chemotherapy for Bladder Cancer.
    J Urol. 2017;197.
    >> Share

    February 2017
  269. STEINBERG GD
    Re: Comparative Effectiveness of Fluorescent versus White Light Cystoscopy for Initial Diagnosis or Surveillance of Bladder Cancer on Clinical Outcomes: Systematic Review and Meta-Analysis: R. Chou, S. Selph, D. I. Buckley, R. Fu, J. C. Griffin, S. Gr
    J Urol. 2017 Feb 6. pii: S0022-5347(16)32070-5. doi: 10.1016/j.juro.2016.
    >> Share

    January 2017
  270. CHANG SS
    Re: Long-Term Follow-up of TaG1 Non-Muscle-Invasive Bladder Cancer.
    J Urol. 2017;197:52-54.
    >> Share

  271. CHANG SS
    Re: PET/Computed Tomography in Renal, Bladder, and Testicular Cancer.
    J Urol. 2017;197:53-54.
    >> Share

    December 2016
  272. BEUKERS W, van der Keur KA, Kandimalla R, Vergouwe Y, et al
    FGFR3, TERT and OTX1 as urinary biomarker combination for surveillance of bladder cancer patients in a large prospective multicenter study.
    J Urol. 2016 Dec 31. pii: S0022-5347(16)32099-7. doi: 10.1016/j.juro.2016.
    >> Share

  273. SHENOY SP, Marla PK, Sharma P, Batchu CK, et al
    Re: Sequential bacillus Calmette-Guerin/Electromotive Drug Administration of Mitomycin C as the Standard Intravesical Regimen in High Risk Nonmuscle Invasive Bladder Cancer: 2-Year Outcomes: C. Gan, S. Amery, K. Chatterton, M. S. Khan, K. Thomas and T
    J Urol. 2016 Dec 28. pii: S0022-5347(16)31927-9. doi: 10.1016/j.juro.2016.
    >> Share

  274. CHOU R, Selph S, Buckley DI, Fu R, et al
    Intravesical Therapy for the Treatment of Non-Muscle-Invasive Bladder Cancer: A Systematic Review and Meta-analysis.
    J Urol. 2016 Dec 24. pii: S0022-5347(16)32091-2. doi: 10.1016/j.juro.2016.
    >> Share

    October 2016
  275. CHOU R, Selph S, Buckley DI, Fu R, et al
    Comparative effectiveness of fluorescent versus white light cystoscopy for initial diagnosis or surveillance of bladder cancer on clinical outcomes: Systematic review and meta-analysis.
    J Urol. 2016 Oct 22. pii: S0022-5347(16)31585-3. doi: 10.1016/j.juro.2016.
    >> Share

  276. ATALA A
    Re: Regulation of UHRF1 by Dual-Strand Tumor-Suppressor MicroRNA-145 (miR-145-5p and miR-145-3p): Inhibition of Bladder Cancer Cell Aggressiveness.
    J Urol. 2016;196:1314.
    >> Share

  277. CHANG SS
    Re: Investigation of Multisequence Magnetic Resonance Imaging for Detection of Recurrent Tumor after Transurethral Resection for Bladder Cancer.
    J Urol. 2016;196:1045.
    >> Share

  278. CHANG SS
    Re: Quality of Life in Patients with Non-Muscle-Invasive Bladder Cancer: One-Year Results of a Multicentre Prospective Cohort Study.
    J Urol. 2016;196:1045-6.
    >> Share

  279. CHANG SS
    Re: Gene Expression Test for the Non-Invasive Diagnosis of Bladder Cancer: A Prospective, Blinded, International and Multicenter Validation Study.
    J Urol. 2016;196:1044-6.
    >> Share

    May 2016
  280. WANG DS
    Re: Long-Term Changes in Renal Function Outcomes following Radical Cystectomy and Urinary Diversion.
    J Urol. 2016;195:1511.
    >> Share

  281. MOREY AF
    Re: Outcomes of the Endoscopic Treatment of Bladder Neck Contractures in the Orthotopic Neobladder.
    J Urol. 2016;195:1508-9.
    >> Share

  282. CHANG SS
    Re: Oncologic Outcomes following Robot-Assisted Radical Cystectomy with Minimum 5-Year Follow-up: The Roswell Park Cancer Institute Experience.
    J Urol. 2016;195:1381-2.
    >> Share

  283. VENKATRAMANI V, Parekh DJ
    Editorial Comment.
    J Urol. 2016;195:1375.
    >> Share

  284. KRISHNAN N, Liu X, Lavieri MS, Hu M, et al
    A Model to Optimize Followup Care and Reduce Hospital Readmissions after Radical Cystectomy.
    J Urol. 2016;195:1362-7.
    >> Share

  285. HUSSEIN AA, Hashmi Z, Dibaj S, Altartir T, et al
    Reoperations following Robot-Assisted Radical Cystectomy: A Decade of Experience.
    J Urol. 2016;195:1368-76.
    >> Share

    April 2016
  286. PATEL S, Cookson MS
    Radical Cystectomy-The Waiting is the Hardest Part...or is it?
    J Urol. 2016;195.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016